目的 探討大株紅景天膠囊聯(lián)合苯磺酸氨氯地平膠囊治療冠心病心絞痛的臨床療效。方法 選取2020年2月—2021年5月在天津市寧河區(qū)醫(yī)院接受治療的94例冠心病心絞痛患者，按照隨機數(shù)字表法將94例患者分為對照組和治療組，每組各包括47例患者。對照組患者口服苯磺酸氨氯地平膠囊，10 mg/次，1次/d。治療組在對照組治療的基礎(chǔ)上口服大株紅景天膠囊，4粒/次，3次/d。兩組患者連續(xù)治療2個月。觀察兩組的臨床療效，比較兩組患者心絞痛癥狀、心功能指標和血管內(nèi)皮功能指標水平。結(jié)果 治療后，治療組總有效率為95.74%，對照組總有效率為80.85%，組間有明顯差異（P<0.05）。治療后，兩組心絞痛的發(fā)作頻率、持續(xù)時間、視覺模擬評分法（VAS）均顯著降低（P<0.05）；與對照組相比，治療組心絞痛的發(fā)作頻率、持續(xù)時間、VAS評分降低更明顯（P<0.05）。治療后，兩組的左室射血分數(shù)（LVEF）明顯升高，左心房內(nèi)徑（LAD）、舒張期室間隔厚度（IVST）明顯降低（P<0.05）；治療后，治療組的LVEF高于對照組，LAD、IVST低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組的一氧化氮合成酶（eNOS）水平明顯升高，內(nèi)皮素-1（ET-1）、血栓素A2（TXA2）水平明顯降低，差異有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組的eNOS水平比對照組高，ET-1、TXA2水平比對照組低，差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 大株紅景天膠囊聯(lián)合苯磺酸氨氯地平膠囊治療冠心病心絞痛的療效確切，能減輕心絞痛癥狀，改善心功能和血管內(nèi)皮功能，安全性良好。

Objective To investigate the clinical efficacy of Dazhuhongjingtian Capsules combined with Amlodipine Besylate Capsules in treatment of angina pectoris of coronary heart disease. Methods Patients (94 cases) with angina pectoris of coronary heart disease in Tianjin Ninghe Hospital from February 2020 to May 2021 were divided into control and treatment groups according to the random number table method, and each group had 47 cases. Patients in the control group were po administered with Amlodipine Besylate Capsules, 10 mg/time, once daily. Patients in the treatment group were po administered with Dazhuhongjingtian Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and angina symptoms, cardiac function indexes and vascular endothelial indexes in two groups were compared. Results After treatment, the total effective rate was 95.74% in the treatment group and 80.85% in the control group, and there was a significant difference between two groups (P < 0.05). After treatment, the attack frequency and duration of angina pectoris and the VAS scores in two groups were significantly decreased (P < 0.05). Compared with the control group, the attack frequency and duration of angina pectoris and the VAS scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the LVEF in two groups were significantly increased, but the LAD and IVST in two groups were significantly decreased (P < 0.05). After treatment, the LVEF in the treatment group was higher than that in the control group, but the LAD and IVST in the treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of eNOS in two groups were significantly increased, but the levels of ET-1 and TXA₂ in two groups were significantly decreased (P < 0.05). After treatment, the levels of eNOS in the treatment group were higher than those in the control group, but the levels of ET-1 and TXA₂ were lower than those in the control group (P < 0.05). Conclusion Dazhuhongjingtian Capsules combined with Amlodipine Besylate Capsules has clinical curative effect in treatment of angina pectoris of coronary heart disease, can reduce the symptoms of angina pectoris, improve cardiac function and vascular endothelial function, with good safety.

R972

河北省中醫(yī)藥管理局科研計劃項目（2019311）